52

Hikal LtdBOM 524735 Stock Report

Last reporting period 31 Mar, 2024

Updated 13 Nov, 2024

Last price

Market cap $B

0.213

Micro

Exchange

XBOM - Bombay Stock Exchange

524735.BO Stock Analysis

52

Avoid

Based on Eyestock quantitative analysis, 524735.BO`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

37/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-41.7 %

Greatly overvalued

Market cap $B

0.213

Dividend yield

0.55 %

Shares outstanding

123.3 B

Hikal Ltd. engages in the manufacture of chemical intermediates, specialty chemicals, active pharma ingredients, and contract research activities. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,142 full-time employees. The firm operates through two segments: pharmaceuticals and crop protection. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. The Company’s products and services include gabapentin; thiabendazole, and diuron contract development and custom manufacturing of intermediates; application programming interface (APIs); and artificial intelligence (AI’s). The firm supplies its products to customers across the globe in the United States, Japan, Europe, Canada, Southeast Asia, Latin American, India and RoW.

View Section: Eyestock Rating